Metabolic & Cardiometabolic · Gut & Microbiome
food-derived peptides inhibits DPP-4
In plain terms: Can food proteins block DPP-4, the enzyme that breaks down the blood-sugar hormone GLP-1?
Strong support Metabolic & Cardiometabolic 🐭 Non-human evidence
RefutedContestedStrong support
consensus score 0.95
Yes, but only shown in the lab and animals so far, and not yet proven in bread or people.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: Animal studies (Animal)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
31 support 0 contradict 0 tested null 1 mixed · 32 sources, 31 independent groups
What the evidence shows
Peptides from whey, cereal (Coix) and other plant proteins inhibit DPP-4 in vitro (up to ~97%) and raise active GLP-1 in mice — but the bread-relevant ones required targeted enzymatic hydrolysis (not LAB fermentation) and their release in bread, gut survival and absorption are unproven.
The evidence (32)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Wang 2024 · Food Res Int | animal | supports | moderate | Baltic herring hydrolysate peptides predicted DPP-4 inhibitors; improved glucose tolerance, raised GLP-1 in mice. |
| Takemori K et al 2026 · Preprints.org | animal | mixed | moderate | Food-derived (bonito) elastin peptides raised plasma GLP-1/insulin and improved glucose tolerance in hypertensive rats (SHRSP) in vivo, and downregulated renal Dpp4 gene expression, but the authors explicitly attribute the metabolic benefit |
| Ojha P et al 2025 · study_type: observational | in-vitro | supports | moderate | Narrative review on in-vitro-simulated-digestion-derived bioactive peptides for T2DM management, discussing enzyme-inhibition mechanisms generically; notes efficacy validated mainly in vitro/in silico with limited clinical trial data. |
| Zhang et al. 2023 · J Agric Food Chem | in-vitro | supports | moderate | Coix-seed prolamin peptides 97% DPP-IV inhibition LPFYPN IC50 70uM. IN-VITRO; needs targeted hydrolysis |
| Patlan-Velázquez LF et al 2026 · study_type: in-vitro | in-vitro | supports | low | LAB co-culture-fermented whey used to make Requeson cheese produced peptide extracts with only modest DPP-IV inhibition (14.2%), versus stronger ACE-I inhibition (31.8%); in-vitro assay only. |
| Zhao X et al 2026 · study_type: animal | animal | supports | moderate | Yellowfin tuna hydrolysate lowered blood glucose and raised insulin in streptozotocin-diabetic mice in vivo; sub-fractions showed in-vitro α-amylase and DPP-IV inhibitory activity, with peptides identified via in-silico analysis. |
| Zheng Q et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Lentinula edodes (shiitake) stem protein hydrolysate fraction had DPP-IV IC50 0.091 mg/mL; three synthesized peptides (EW-1, WR-2, LP-3) showed >60% DPP-IV inhibition at 1 mg/mL, Caco-2 safety confirmed, no in-vivo data. |
| Fanzaga M et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Tripeptide-enriched collagen hydrolysate (CH) showed dose-dependent DPP-IV inhibition in enzymatic assay, reduced cellular DPP-IV activity in Caco-2 cells, and stimulated GLP-1 secretion in STC-1 enteroendocrine cells (cell-based, not in-vi |
| Amigo-Benavent M et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Hemp seed (Alcalase+Flavourzyme) hydrolysate peptide TNGPQLIH inhibited DPP-IV in vitro (IC50 1.70 mg/mL), with activity generally conserved or improved after INFOGEST simulated digestion; no in-vivo testing. |
| Liu 2026 · J Dairy Sci | in-vitro | supports | moderate | Goat milk-derived peptides MMSF, MPFPK, GPFPIL competitively inhibited DPP-4 (IC50 0.32-2.83 mM) in vitro. |
| Gan J et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Two synthesized quinoa-derived pentapeptides (WLAFR, LLPFR) competitively inhibited DPP-IV in vitro with IC50 ~78µM and ~130µM respectively; kinetics/spectroscopy plus docking elucidated binding mechanism, no in-vivo testing. |
| Fleury 2022 · Int J Mol Sci | animal | supports | moderate | Seven food proteins compared in vitro vs in vivo: DPP-IV inhibition varied; in vivo plasma effects weaker than in vitro. |
| Xu et al. 2019 · J Agric Food Chem | in-vitro | supports | moderate | Rapeseed napin hydrolysate IC50 0.68mg/mL; peptides dock DPP-IV. IN-VITRO only |
| Takemori 2026 · Nutrients | in-vitro | supports | moderate | Food elastin peptides improved glucose metabolism and raised GLP-1 despite only modest DPP-4 inhibition. |
| An 2025 · J Dairy Sci | in-vitro | supports | moderate | Flavorzyme hydrolysis of buffalo casein increased DPP-4 inhibition with identified bioactive peptides. |
| Laosam P et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Goat blood (Neutrase) hydrolysate and its ≤3kDa fraction showed 81-87.8% DPP-IV inhibition in vitro; Caco-2 transport assay confirmed 10.47% absorption of the peptides with retained activity, no in-vivo glycemic data. |
| Ramirez-Lozano F et al 2025 · study_type: mechanism | mechanism | supports | low | Black bean ('Vaina Morada') protein hydrolysate peptides were experimentally confirmed to inhibit α-amylase/α-glucosidase; DPP-IV inhibition is only generically asserted as 'potential' from in-silico prediction, with no DPP-IV-specific IC50 |
| Han B et al 2026 · study_type: animal | animal | supports | moderate | Goat milk peptide IPPK inhibited DPP-IV in vitro (IC50 120.17µM) and lowered blood glucose in mice in vivo, associated with DPP-IV inhibition and increased GLP-1 levels. |
| Shen F et al 2026 · study_type: animal | animal | supports | moderate | Wheat peptides LPQ/LPQF showed potent DPP-IV inhibitory activity in vitro and normalized glycemic levels in an in-vivo hyperglycemic zebrafish model; broader wheat-peptide intervention also improved glucose tolerance in HFD mice via multi-t |
| Rai & Priyadarshini 2023 · Eur J Nutr | animal | supports | moderate | Whey hydrolysate inhibited DPP-4, raised serum/brain GLP-1, cut weight HFD mice. ANIMAL |
| Zhu Y et al 2025 · study_type: in-vitro | in-vitro | supports | moderate | Six mealworm (Tenebrio molitor)-derived peptides dually inhibited α-glucosidase and DPP-IV in vitro and enhanced glucose consumption in insulin-resistant HepG2 cells; docking elucidated binding, no in-vivo data. |
| Yan C et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Defatted walnut meal peptides FPAG (IC50 105.6µM) and LPSYQPTP (IC50 132.4µM) inhibited DPP-IV in vitro, retained activity after simulated GI digestion, and enhanced active GLP-1 secretion in STC-1 enteroendocrine cells. |
| Suryaningtyas 2025 · Int Immunopharmacol | animal | supports | moderate | Mussel peptides PIISVYWK/FSVVPSPK inhibited DPP-IV, raised GLP-1, improved glycemia in T2D mice. |
| Antony 2024 · Int J Mol Sci | mechanism | supports | low | Molecular docking/MD: hemorphin food peptides bind DPP-IV active site (S1/S2 pockets), supporting inhibition. |
| Handayani FW et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Bitter leaf (Vernonia amygdalina) thermolysin hydrolysate yielded peptide VAYPQCV (VV7), a competitive DPP-IV inhibitor with IC50 19.8µM; in-vitro assay plus docking, remained intact after simulated GI digestion (not tested in vivo). |
| Chen W et al 2026 · study_type: mechanism | mechanism | supports | low | Morchella esculenta lectin MEP5's main action is α-glucosidase docking; 11 short oligopeptides released by simulated digestion were computationally screened and predicted (via docking) as DPP-IV inhibitors, but none were synthesized or wet- |
| Mitsui 2025 · Foods | in-vitro | supports | moderate | Buckwheat-flour peptides inhibited DPP-4; hydrolysate improved oral glucose tolerance in rats. |
| Mongkolnkrajang U et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Bee pollen protein hydrolysate peptide ATHALLA (AA-7) inhibited DPP-IV in vitro (IC50 52.63µM vs diprotin A's 22.4µM) and modulated glucose transporter (SGLT1/GLUT2) expression in Caco-2 cells; poor predicted intestinal absorption (in-silic |
| Qin X et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Sea buckthorn leaf protein trypsin hydrolysate peptide VG-11 dually inhibited α-glucosidase and DPP-IV in vitro, IC50 0.2611±0.021 mM for DPP-IV, confirmed via docking and solid-phase synthesis, no in-vivo data. |
| Khaliq M et al 2026 · study_type: observational | observational | supports | low | Narrative review of algal peptides across in-vitro, animal and limited human intervention studies reports DPP-IV inhibition as one of several mechanisms (alongside ACE, α-amylase/glucosidase); notes clinical translation is limited by uncert |
| Takenoyama S et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | Beef, pork and chicken (Protamex) hydrolysates inhibited DPP-IV ~70% in vitro (IC50 3.2-3.9 mg/mL); a chicken hydrolysate tablet retained inhibitory activity after processing; in-vitro assay only. |
| Tan J et al 2026 · study_type: in-vitro | in-vitro | supports | moderate | AI-guided screening of goat blood proteins identified two novel DPP-IV inhibitory peptides (FPL, competitive; FPHFDL, non-competitive), confirmed by in-vitro assay, kinetics, docking and digestive-stability testing; no in-vivo data. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.